+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Sibutramine"

Antiobesity Global Market Report 2024 - Product Thumbnail Image

Antiobesity Global Market Report 2024

  • Report
  • November 2023
  • 175 Pages
  • Global
From
Obesity - Pipeline Insight, 2024 - Product Thumbnail Image

Obesity - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 260 Pages
  • Global
From
Anti-Obesity Drugs Industry Forecasts - China Focus - Product Thumbnail Image

Anti-Obesity Drugs Industry Forecasts - China Focus

  • Report
  • November 2023
  • 87 Pages
  • China
From
From
Anti-Obesity Drugs Markets in China - Product Thumbnail Image

Anti-Obesity Drugs Markets in China

  • Report
  • November 2023
  • 211 Pages
  • China
From
  • 7 Results (Page 1 of 1)
Loading Indicator

Sibutramine is an anti-obesity drug that was first approved by the US Food and Drug Administration (FDA) in 1997. It works by inhibiting the reuptake of serotonin and norepinephrine, two neurotransmitters that regulate appetite. It is usually prescribed to people who are obese or overweight and have not been able to lose weight through diet and exercise alone. The drug is available in both oral and injectable forms. Sibutramine has been used to treat obesity for over two decades, but its use has declined in recent years due to safety concerns. In 2010, the FDA issued a warning about the potential for increased risk of heart attack and stroke associated with the drug. As a result, many countries have removed sibutramine from the market. Despite the safety concerns, sibutramine remains a popular anti-obesity drug in some countries. It is available in generic form in many countries, including India, Mexico, and Brazil. It is also available in brand name form from several pharmaceutical companies, including Merck, Pfizer, and Novartis. Show Less Read more